G

Generation Bio Co

GBIO

3.15000
USD
-0.19
(-5.69%)
Market Closed
Volume
3,247
EPS
0
Div Yield
0
P/E
-1
Market Cap
145,495,762
Related Instruments
AMGN
2.78
(0.84%)
335.22 USD
B
BIIB
-2.500
(-1.17%)
210.710 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
GILD
0.470
(0.62%)
76.510 USD
MRNA
-25.020
(-20.99%)
94.160 USD
REGN
13.14
(1.22%)
1,091.19 USD
TMO
9.03
(1.47%)
621.78 USD
VRTX
9.75
(1.97%)
505.40 USD
News

Title: Generation Bio Co

Sector: Healthcare
Industry: Biotechnology
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.